A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

OBJECTIVES: To determine the safety, efficacy and pharmacokinetic (PK) profile of a pre-mixed depot formulation of leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg for up to 1 year of treatment for subjects with advanced prostate cancer. PATIENTS AND METHODS: In this open-label, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal, Mincik, Ivan, DeGuenther, Mark, Student, Vladimir, Jievaltas, Mindaugas, Patockova, Jitka, Simpson, Kelle, Hu, Chu-Hsuan, Huang, Shih-Tsung, Li, Yuhua, Lee, Yisheng, Chien, Ben, Mao, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954127/
https://www.ncbi.nlm.nih.gov/pubmed/30941562
http://dx.doi.org/10.1007/s00345-019-02741-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954127/
https://www.ncbi.nlm.nih.gov/pubmed/30941562
http://dx.doi.org/10.1007/s00345-019-02741-7

Ejemplares similares